During the past decade, Johns Hopkins Asthma And Allergy Center conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 15 clinical trials were completed, i.e. on average, 115.4% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 4 clinical trials were completed. i.e. 57.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Johns Hopkins Asthma And Allergy Center" #1 sponsor was "Johns Hopkins University" with 16 trials, followed by "Eli Lilly and Company" with 2 trials sponsored, "Amgen" with 1 trials sponsored, "Arena Pharmaceuticals" with 1 trials sponsored and "Boehringer Ingelheim" with 1 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Johns Hopkins Asthma And Allergy Center" #1 collaborator was "Genentech, Inc." with 3 trials as a collaborator, "National Institute of Allergy and Infectious Diseases (NIAID)" with 3 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 2 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator and "Centers for Medicare and Medicaid Services" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "Johns Hopkins Asthma And Allergy Center" are "Asthma" (6 trials), "COPD" (3 trials), "Allergic Rhinitis" (2 trials), "Cat Allergy" (2 trials) and "Chronic Bronchitis" (2 trials). Many other conditions were trialed in "Johns Hopkins Asthma And Allergy Center" in a lesser frequency.

Most popular intervention types in "Johns Hopkins Asthma And Allergy Center" are "Drug" (19 trials), "Device" (5 trials), "Other" (5 trials), "Biological" (2 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "Omalizumab" (4 trials), "omalizumab" (2 trials), "AMG 157" (1 trials) and "AMG 157 Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Johns Hopkins Asthma And Allergy Center" are 28 trials for "All" genders.

Currently, there are NaN active trials in "Johns Hopkins Asthma And Allergy Center". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 19 completed trials in Johns Hopkins Asthma And Allergy Center, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Johns Hopkins Asthma And Allergy Center, 2 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 2 trials that are defined as “Not Applicable".